SOCIETY FOR MEDICINES RESEARCH
The objects of the Charity are the advancement of science relating to all aspects of drug research, primarily byproviding a common meeting ground for all who are interested and involved in such research, with the purposeof furthering the education of such persons to be of ultimate benefit to the general public in the field of relief ofsickness.
Financial health, per its FY2025 accounts
The accounts state that unrestricted funds increased from £30,417 to £44,284, driven by a significant rise in meeting registration income and sponsorship. The trustees report adequate resources for the foreseeable future and note that funds are held as cash balances rather than investments.
What the accounts disclose
“Meeting registrations Fees receivable 44,629”
“It is the policy of the Trustees to retain a fund of such value as to provide for any unexpected expenditure on normal activities not covered by related income.” — page 5
Trustees
- Daniel O'Donovanchair
- Dr Sam Butterworth
- Pamela Brown
- Richard Davenport
Income and spending
| Financial year end | Income | Spending |
|---|---|---|
| 31/05/2025 | £79k | £66k |
| 31/05/2024 | £29k | £40k |
| 31/05/2023 | £41k | £34k |
| 31/05/2022 | £29k | £33k |
| 31/05/2021 | £59k | £57k |
Common questions
Is SOCIETY FOR MEDICINES RESEARCH financially healthy?
Per its FY2025 accounts: The accounts state that unrestricted funds increased from £30,417 to £44,284, driven by a significant rise in meeting registration income and sponsorship. The trustees report adequate resources for the foreseeable future and note that funds are held as cash balances rather than investments. Its FY2025 accounts were independently examined.